Which class is listed as baseline medications for heart failure management?

Which class is listed as baseline medications for heart failure management?

• A. Calcium channel blockers
• B. Hydralazine
• C. Nitrates
• D. ARNI/ACEi/ARBs

Answer: (D)

The main concept is that certain neurohormonal blocking therapies are the foundational treatments in heart failure because they have been proven to improve survival and reduce hospitalization. Medications that inhibit the renin-angiotensin-aldosterone system address the drivers of remodeling and fluid retention, helping to reverse or slow disease progression. ACE inhibitors and ARBs directly block angiotensin II effects, lowering afterload, reducing preload, and limiting adverse cardiac remodeling. An angiotensin receptor–neprilysin inhibitor combines RAAS blockade with enhanced natriuretic peptide activity, providing additional vasodilation, natriuresis, and anti-remodeling effects; this class has shown superior outcomes in trials compared with ACE inhibitors alone, making it a strong baseline option when tolerated. Because of these mortality and morbidity benefits, these agents form the core starting point for most patients with systolic heart failure, adjusted for blood pressure and kidney function. Calcium channel blockers, on the other hand, do not carry the same mortality benefit in systolic heart failure and can worsen outcomes in some patients, so they are not considered baseline therapy for this condition. Hydralazine with nitrates can be beneficial as an add-on in specific populations or when ACE inhibitors/ARBs are not tolerated, but it is not universally used as first-line baseline therapy. The key idea is that blocking RAAS activity at baseline addresses the central pathophysiology driving heart failure, which is why ARNI/ACEi/ARBs sit at the top of the initial treatment plan.

The main concept is that certain neurohormonal blocking therapies are the foundational treatments in heart failure because they have been proven to improve survival and reduce hospitalization. Medications that inhibit the renin-angiotensin-aldosterone system address the drivers of remodeling and fluid retention, helping to reverse or slow disease progression. ACE inhibitors and ARBs directly block angiotensin II effects, lowering afterload, reducing preload, and limiting adverse cardiac remodeling. An angiotensin receptor–neprilysin inhibitor combines RAAS blockade with enhanced natriuretic peptide activity, providing additional vasodilation, natriuresis, and anti-remodeling effects; this class has shown superior outcomes in trials compared with ACE inhibitors alone, making it a strong baseline option when tolerated. Because of these mortality and morbidity benefits, these agents form the core starting point for most patients with systolic heart failure, adjusted for blood pressure and kidney function.

Calcium channel blockers, on the other hand, do not carry the same mortality benefit in systolic heart failure and can worsen outcomes in some patients, so they are not considered baseline therapy for this condition. Hydralazine with nitrates can be beneficial as an add-on in specific populations or when ACE inhibitors/ARBs are not tolerated, but it is not universally used as first-line baseline therapy. The key idea is that blocking RAAS activity at baseline addresses the central pathophysiology driving heart failure, which is why ARNI/ACEi/ARBs sit at the top of the initial treatment plan.